Article
Pembrolizumab for the better treatment of EGFR-mutant T790M-negative advanced lung adenocarcinoma patients than dual treatment of pemetrexed plus platinum after tyrosine kinase inhibitor treatment failure.
Annals of palliative medicine - 1 Jun 2022
Lu Zhuming, Ye Ming, Sun Tao, Wu Suoyun, Lin Zhichao, Zhang Xin, Rao Dongping, Zhang Dongxi, Ke Yongwen, Chen Zhuowen
Abstract excerpt
BACKGROUND: The treatment of lung cancer patients, especially those with epidermal growth factor receptor (EGFR)-mutant T790M-negative adenocarcinoma, after first- or second-line tyrosine kinase inhibitor (TKI) treatment failure is challenging due to the poor prognosis and limited effectiveness of platinum two-drug chemotherapy or chemotherapy plus anti-angiogenesis therapy. It is well-known that pembrolizumab...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.